Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâre developing a new type of targeted therapy that ââŚrelies on knowledge from an RNA-based diagnostic instead of more traditional DNA-based diagnostics to determine if a patient with cancer is a candidate for our targeted therapy.â They believe that this type of diagnostic will help unlock targeted therapies for the 70% of cancer patients who do not have âdruggableâ genetic mutations in their DNA. So far, Nemucore has raised $7M from foundation grants and the National Cancer Institute; they have over 57 investors; and leading experts at Memorial Sloan Kettering and Moffitt Cancer Centers are set to perform their clinical trial. Plus, their leadership team has over 100 years of biopharmaceutical experience. The bottom line? Nemucore wants, with this campaign, to âcure AML together and open a new future of cancer care.â Source
No articles found.
MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedica...
MorphoSys (FSE & NASDAQ: MOR) is a clinical-sta...
As a leading provider of innovative technologies for the treatment of Atrial Fibri...
As a leading provider of innovative technologie...
Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) is a medical technology compan...
Axonics Modulation Technologies, Inc. (NASDAQ:A...
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...
Magenta Therapeutics is a clinical-stage biotec...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the deve...
Pacira BioSciences, Inc. is a specialty pharmac...
Unum Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Unum Therapeutics is a clinical-stage biopharma...
Join the National Investor Network and get the latest information with your interests in mind.